Mechanism of action of indomethacin in indomethacin-responsive headaches

Current Pain and Headache Reports

Volumn 17, Issue , 2013, Pages

  Summ, Oliver ^a   Evers, Stefan ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Krankenhaus Lindenbrunn   (Germany)

Author keywords

COX; Cyclooxygenase; Headache; Hemicrania continua; Indomethacin; Mechanism; Nitric oxide; NO; Non steroidal anti inflammatory drug; NSAID; Paroxysmal hemicrania; TAC; Trigeminal autonomic cephalalgia

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; CAFFEINE; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; FLUNARIZINE; GLYCERYL TRINITRATE; IBUPROFEN; INDOMETACIN; LIDOCAINE; LITHIUM SALT; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN; NAPROXEN; NIMESULIDE; PARACETAMOL; PHOSPHOLIPASE A2; PROCHLORPERAZINE; SUMATRIPTAN; TOPIRAMATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER RESEARCH; CLINICAL EFFECTIVENESS; CLUSTER HEADACHE; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; EXERTIONAL HEADACHE; HEADACHE; HEMICRANIA CONTINUA; HUMAN; HYPNIC HEADACHE; MIGRAINE; NEUROPROTECTION; NONHUMAN; PAIN THRESHOLD; PAROXYSMAL HEMICRANIA; PATHOPHYSIOLOGY; PRIMARY MEDICAL CARE; TENSION HEADACHE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT; METABOLISM; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-BRAIN BARRIER; CYCLOOXYGENASE INHIBITORS; HEADACHE; HUMANS; INDOMETHACIN; TREATMENT OUTCOME;

EID: 84886655595     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-013-0327-x     Document Type: Article

References (77)

1. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968-81.
2. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache—report of an EFNS task force. Eur J Neurol. 2010;17(11):1318-25.
3. May A, Leone M, Afra J, Linde M, Sandor PS, Evers S, et al. EFNS guidelines on the treatment of cluster headache and other trigeminalautonomic cephalalgias. Eur J Neurol. 2006;13(10):1066-77.
4. Headache Classification Committee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.
5. Evers S, Goadsby P, Jensen R, May A, Pascual J, Sixt G. Treatment of miscellaneous idiopathic headache disorders (Group 4 of the IHS classification)—report of an EFNS task force. Eur J Neurol. 2011;18(6):803-12. A review on therapeutic options of miscellaneous headaches that demonstrates the outstanding role of indomethacin as a treatment option in these headache entities.
6. Martins IP, Parreira E, Costa I. Extratrigeminal ice-pick status. Headache. 1995;35(2):107-10.
7. Ammache Z, Graber M, Davis P. Idiopathic stabbing headache associated with monocular visual loss. Arch Neurol. 2000;57(5):745-6.
8. Mathew NT. Indomethacin responsive headache syndromes. Headache. 1981;21(4):147-50.
9. Raskin NH. The cough headache syndrome: treatment. Neurology. 1995;45(9):1784.
10. Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache. 1999;39(6):437-8.
11. Diamond S. Prolonged benign exertional headache: its clinical characteristics and response to indomethacin. Headache. 1982;22(3):96-8.
12. Dodick DW. Indomethacin-responsive headache syndromes. Curr Pain Headache Rep. 2004;8(1):19-26.
13. Frese A, Rahmann A, Gregor N, Biehl K, Husstedt IW, Evers S. Headache associated with sexual activity: prognosis and treatment options. Cephalalgia. 2007;27(11):1265-70.
14. Gelfand AA, Goadsby PJ. Primary sex headache in adolescents. Pediatrics. 2012;130(2):e439-41.
15. Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache. 2006;46(7):1205-6.
16. Pinessi L, Rainero I, Cicolin A, Zibetti M, Gentile S, Mutani R. Hypnic headache syndrome: association of the attacks with REM sleep. Cephalalgia. 2003;23(2):150-4.
17. Prakash S, Dabhi AS. Relapsing remitting hypnic headache responsive to indomethacin in an adolescent: a case report. J Headache Pain. 2008;9(6):393-5.
18. Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia. 2007;27(9):1082-4.
19. Martins IP, Gouveia RG. Hypnic headache and travel across time zones: a case report. Cephalalgia. 2001;21(9):928-31.
20. Ghiotto N, Sances G, Di Lorenzo G, Trucco M, Loi M, Sandrini G, et al. Report of eight new cases of hypnic headache and minireview of the literature. Funct Neurol. 2002;17(4):211-9.
21. Evers S, Rahmann A, Schwaag S, Ludemann P, Husstedt IW. Hypnic headache—the first German cases including polysomnography. Cephalalgia. 2003;23(1):20-3.
22. Seidel S, Zeitlhofer J, Wober C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia. 2008;28(10):1086-90.
23. Peters N, Lorenzl S, Fischereder J, Botzel K, Straube A. Hypnic headache: a case presentation including polysomnography. Cephalalgia. 2006;26(1):84-6.
24. Centonze V, D'Amico D, Usai S, Causarano V, Bassi A, Bussone G. First Italian case of hypnic headache, with literature review and discussion of nosology. Cephalalgia. 2001;21(1):71-4.
25. Lisotto C, Rossi P, Tassorelli C, Ferrante E, Nappi G. Focus on therapy of hypnic headache. J Headache Pain. 2010;11(4):349-54.
26. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997;120(Pt 1):193-209.
27. Porta-Etessam J, Cuadrado M, Rodriguez-Gomez O, Garcia-Ptacek S, Valencia C. Are Cox-2 drugs the second line option in indomethacin responsive headaches? J Headache Pain. 2010;11(5):405-7.
28. Cittadini E, Goadsby PJ. Update on hemicrania continua. Curr Pain Headache Rep. 2011;15(1):51-6.
29. Morelli N, Mancuso M, Felisati G, Lozza P, Maccari A, Cafforio G, et al. Does sphenopalatine endoscopic ganglion block have an effect in paroxysmal hemicrania? A case report. Cephalalgia. 2010;30(3):365-7.
30. Akerman S, Holland PR, Summ O, Lasalandra MP, Goadsby PJ. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain. 2012;135(Pt 12):3664-75. This article highlights an effect of indomethacin that might arise from interaction with autonomic transmission at the level of the sphenopalatine ganglion and is possibly relevant to the treatment of trigeminoautonomic cephalalgias.
31. Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, Caparso A, May A. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia 2013, in press.
32. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981;6(4):245-58.
33. Alvan G, Orme M, Bertilsson L, Ekstrand R, Palmer L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975;18(3):364-73.
34. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440-9.
35. Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res. 2006;23(5):873-81.
36. Summ O, Andreou AP, Akerman S, Goadsby PJ. A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain. 2010;11(6):477-83. This article identified an interaction of indomethacin with NO-mechanisms that was not shown by other drugs of the NSAID class. It implicates a possible importance to indomethacin’s mechanism of action in indomethacin-sensitive headaches.
37. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339(Pt 3):607-14.
38. Noreen Y, Ringbom T, Perera P, Danielson H, Bohlin L. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998;61(1):2-7.
39. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693-7.
40. Black WC, Bayly C, Belley M, Chan CC, Charleson S, Denis D, et al. From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 1996;6(6):725-30.
41. Kaplan L, Weiss J, Elsbach P. Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1978;75(6):2955-8.
42. Joachim A, Lautscham E, Christoffers J, Ruttkowski B. Oesophagostomum dentatum: effect of glutathione S-transferase (GST) inhibitors on GST activity and larval development. Exp Parasitol. 2011;127(4):762-7. Indomethacins capabilities in gluthation S transferase inhibition were demonstrated.
43. Hayeshi R, Chinyanga F, Chengedza S, Mukanganyama S. Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro. J Enzyme Inhib Med Chem. 2006;21(5):581-7.
44. Vandenberghe Y, Ratanasavanh D, Glaise D, Guillouzo A. Influence of medium composition and culture conditions on glutathione S-transferase activity in adult rat hepatocytes during culture. In Vitro Cell Dev Biol. 1988;24(4):281-8.
45. Cerbo R, Centonze V, Grazioli I, Tavolato B, Trenti T, Uslenghi C, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol. 2005;12(10):759-67.
46. Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache. 1998;38(2):122-8.
47. Antonaci F, Sandrini G, Danilov A, Sand T. Neurophysiological studies in chronic paroxysmal hemicrania and hemicrania continua. Headache. 1994;34(8):479-83.
48. Marmura MJ, Silberstein SD, Gupta M. Hemicrania continua: who responds to indomethacin? Cephalalgia. 2009;29(3):300-7.
49. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010;133(Pt 7):1973-86.
50. Cohen AS, Matharu MS, Goadsby PJ. Trigeminal autonomic cephalalgias: current and future treatments. Headache. 2007;47(6):969-80.
51. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol. 1989;165(2-3):251-8.
52. Bakken IJ, Vincent MB, White LR, Cappelen J, Skaanes KO, Sjaastad O. Low concentrations of lithium and cyclooxygenase inhibitors enhance endothelin-1 (ET-1)-induced contractions in human temporal artery, but not in porcine ophthalmic artery. Headache. 1992;32(10):475-9.
53. Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U, et al. IL-1beta stimulates COX-2 dependent PGE(2) synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011;6(3):e17360.
54. Andreou AP, Summ O, Charbit AR, Romero-Reyes M, Goadsby PJ. Animal models of headache: from bedside to bench and back to bedside. Expert Rev Neurother. 2010;10(3):389-411.
55. Gupta S, Bhatt DK, Boni LJ, Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia. 2010;30(1):27-36.
56. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol. 2002;452(2):223-8.
57. Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004;24(2):110-9.
58. Iversen HK. Humanmigrainemodels. Cephalalgia. 2001;21(7):781-5.
59. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996;16(6):412-8.
60. Ekbom K. Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol. 1968;19(5):487-93.
61. Giffin NJ. Paroxysmal hemicrania triggered by GTN. Cephalalgia. 2007;27(8):953-4.
62. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19(2):115-27.
63. Strecker T, Dux M, Messlinger K. Increase in meningeal blood flow by nitric oxide—interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia. 2002;22(3):233-41.
64. Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol. 1999;21(3):219-25.
65. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45(7):850-61.
66. Ghelardini C, Galeotti N, Grazioli I, Uslenghi C. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. J Pain. 2004;5(8):413-9.
67. de Groot DJ, van der Deen M, Le TK, Regeling A, de Jong S, de Vries EG. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007;97(8):1077-83.
68. Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst. 1983;70(6):1103-5.
69. Roller A, Bahr OR, Streffer J, Winter S, Heneka M, Deininger M, et al. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: The role of COX-1 and MRP. Biochem Bioph Res Co. 1999;259(3):600-5.
70. Ogino M, Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int J Clin Oncol. 2001;6(2):84-9.
71. Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem. 1998;273(32).
72. Lok HC, Suryo Rahmanto Y, Hawkins CL, Kalinowski DS, Morrow CS, Townsend AJ, et al. Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and multidrug resistance protein 1 via dinitrosyl iron complexes. J Biol Chem. 2012;287(1):607-18. This article highlights an interaction of indomethacin with nitric oxide mechanisms, demonstrating an effect of indomethacins on nitric oxide metabolism implicating high relevance to nitric oxide dependent mechanisms, including cell signaling.
73. Kanno T, Yaguchi T, Nagata T, Shimizu T, Tanaka A, Nishizaki T. Indomethacin enhances learning and memory potential by interacting with CaMKII. J Cell Physiol. 2012;227(3):919-26.
74. Kanno T, Yaguchi T, Nagata T, Nishizaki T. Indomethacin activates protein kinase C and potentiates alpha7 ACh receptor responses. Cell Physiol Biochem. 2012;29(1-2):189-96.
75. Kanno T, Tsuchiya A, Shimizu T, Tanaka A, Nishizaki T. Novel indomethacin action: selective and direct activation of protein kinase C-epsilon. Cell Physiol Biochem. 2012;30(3):771-7. Protein kinase C-epsilon has been shown being activated by indomethacin.
76. Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? ActaAnaesthesiol Scand. 2005;49(3):341-50.
77. Kusumi M, Ishizaki K, Kowa H, Adachi Y, Takeshima T, Sakai F, et al. Glutathione S-transferase polymorphisms: susceptibility to migraine without aura. Eur Neurol. 2003;49(4):218-22.